AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$APGE

HENDERSON MICHAEL THOMAS sold (to issuer) 920,941 shares of APGE

HENDERSON MICHAEL THOMAS (Chief Executive Officer) sold (to issuer) 920,941 shares of Apogee Therapeutics, Inc. (APGE) on 2026-09-03.

Original reporting
SEC EDGAR · HENDERSON MICHAEL THOMAS
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$APGE
Bearish
medium confidence
Mentioned
$APGE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$APGEBearishLow
01

Why it matters

The insider sell is a fresh primary disclosure that may influence investor perception and short‑term price action.

02

Market read

First‑report insider sale of a significant portion of the CEO's holdings, likely to affect APGE's stock price.

03

What to watch

Potential upcoming financing or acquisition that prompted the CEO to cash out.

Relevance 5/10Novelty 6/10Timing: today

Background

Form 4 filing disclosed the CEO's complete divestiture of his stake in Apogee Therapeutics.

Company-level read

Ticker impact

$APGEBearishMedium confidence
Context

CEO Michael Thomas sold 920,941 shares, leaving zero holdings.

Expected impact

downward pressure in the short term

Evidence & confidence

Insider sale of nearly a million shares by the chief executive is material for a small‑cap biotech and often precedes price weakness.

Market effects

Sector

May raise concerns for other biotech insiders and could affect sector sentiment.

Regional

Limited to U.S. biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale could be a planned liquidity event unrelated to fundamentals.

Key entities

  • Company
    Apogee Therapeutics, Inc.

    Biotech firm listed on Nasdaq (APGE).

  • Executive
    Michael Thomas

    Chief Executive Officer of Apogee Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

APGE insider trading history →

Related articles

SEP 9
$ABBVHighAI 9/10

Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?

AbbVie (ABBV) completed its $10.9B acquisition of Apogee Therapeutics (APGE) at $135.11 per share. AbbVie also reported positive Phase 3 trial results for etentamig. Q2 2026 revenue for AbbVie rose 10.2% to $16.99B, with adjusted EPS up 22.9% to $3.65. Apogee reported a net loss of $85.9M in Q2 2026. Hedge funds increased stakes in both companies ahead of the deal.

insidermonkey.com3 min
SEP 3
$ABBVHighAI 9/10

AbbVie Completes $10.9 Bln Acquisition Of Apogee Therapeutics

AbbVie (ABBV) completed its $10.9 billion acquisition of Apogee Therapeutics (APGE), paying $135.11 per share. The deal strengthens AbbVie's immunology pipeline, including Apogee's lead asset, zumilokibart, for atopic dermatitis. AbbVie expects the acquisition to be dilutive to earnings until 2032. AbbVie reaffirmed its 2026 EPS guidance of $13.87-$14.07, including a $0.14 per-share dilutive impact. ABBV closed at $261.72, up 0.67%.

rttnews.com2 min
SEP 2
$MMEDMed

Biotech Stocks At 52-Week Highs - MMED +10%, PLSE, SOLV, RPRX, APGE

Several biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.

rttnews.com2 min